Vuk-Pavlović S - Search Results

1

Immunotherapy (APC8015, Provenge) targeting prostatic acid phosphatase can induce durable remission of metastatic androgen-independent prostate cancer: a Phase 2 trial.

Burch PA, Croghan GA, Gastineau DA, Jones LA, Kaur JS, Kylstra JW, Richardson RL, Valone FH, Vuk-Pavlović S. Burch PA, et al. Prostate. 2004 Aug 1;60(3):197-204. doi: 10.1002/pros.20040. Prostate. 2004. PMID: 15176049 Clinical Trial.

2

Priming tissue-specific cellular immunity in a phase I trial of autologous dendritic cells for prostate cancer.

Burch PA, Breen JK, Buckner JC, Gastineau DA, Kaur JA, Laus RL, Padley DJ, Peshwa MV, Pitot HC, Richardson RL, Smits BJ, Sopapan P, Strang G, Valone FH, Vuk-Pavlović S. Burch PA, et al. Clin Cancer Res. 2000 Jun;6(6):2175-82. Clin Cancer Res. 2000. PMID: 10873066 Clinical Trial.

3

Engineering dendritic cell grafts for clinical trials in cellular immunotherapy of cancer: example of chronic myelogenous leukemia.

Dietz AB, Litzow MR, Gastineau DA, Vuk-Pavlović S. Dietz AB, et al. Croat Med J. 2001 Aug;42(4):428-35. Croat Med J. 2001. PMID: 11471194 Free article. Review.

4

Mature myeloid dendritic cells for clinical use prepared from CD14+ cells isolated by immunomagnetic adsorption.

Padley DJ, Dietz AB, Gastineau DA, Vuk-Pavlovic S. Padley DJ, et al. J Hematother Stem Cell Res. 2001 Jun;10(3):427-9. doi: 10.1089/152581601750289037. J Hematother Stem Cell Res. 2001. PMID: 11454318 Clinical Trial. No abstract available.

5

Testing the safety of clinical-grade mature autologous myeloid DC in a phase I clinical immunotherapy trial of CML.

Litzow MR, Dietz AB, Bulur PA, Butler GW, Gastineau DA, Hoering A, Fink SR, Letendre L, Padley DJ, Paternoster SF, Tefferi A, Vuk-Pavlović S. Litzow MR, et al. Cytotherapy. 2006;8(3):290-8. doi: 10.1080/14653240600735743. Cytotherapy. 2006. PMID: 16793737 Clinical Trial.

6

Preparing clinical-grade myeloid dendritic cells by electroporation-mediated transfection of in vitro amplified tumor-derived mRNA and safety testing in stage IV malignant melanoma.

Markovic SN, Dietz AB, Greiner CW, Maas ML, Butler GW, Padley DJ, Bulur PA, Allred JB, Creagan ET, Ingle JN, Gastineau DA, Vuk-Pavlovic S. Markovic SN, et al. J Transl Med. 2006 Aug 15;4:35. doi: 10.1186/1479-5876-4-35. J Transl Med. 2006. PMID: 16911798 Free PMC article.

7

Malignant melanoma in the 21st century: the emerging molecular landscape.

Sekulic A, Haluska P Jr, Miller AJ, Genebriera De Lamo J, Ejadi S, Pulido JS, Salomao DR, Thorland EC, Vile RG, Swanson DL, Pockaj BA, Laman SD, Pittelkow MR, Markovic SN; Melanoma Study Group of Mayo Clinic Cancer Center. Sekulic A, et al. Mayo Clin Proc. 2008 Jul;83(7):825-46. doi: 10.4065/83.7.825. Mayo Clin Proc. 2008. PMID: 18613999 Free PMC article. Review.

8

Clinical-grade manufacturing of DC from CD14+ precursors: experience from phase I clinical trials in CML and malignant melanoma.

Dietz AB, Padley DJ, Butler GW, Maas ML, Greiner CW, Gastineau DA, Vuk-Pavlović S. Dietz AB, et al. Cytotherapy. 2004;6(6):563-70. doi: 10.1080/14653240410005357-1. Cytotherapy. 2004. PMID: 15773024

9

Immunosuppressive CD14+HLA-DRlow/- monocytes in prostate cancer.

Vuk-Pavlović S, Bulur PA, Lin Y, Qin R, Szumlanski CL, Zhao X, Dietz AB. Vuk-Pavlović S, et al. Prostate. 2010 Mar 1;70(4):443-55. doi: 10.1002/pros.21078. Prostate. 2010. PMID: 19902470 Free PMC article.

10

Paying the price for standing tall: Fluid mechanics of prostate pathology.

Gat Y, Joshua S, Vuk-Pavlović S, Goren M. Gat Y, et al. Among authors: vuk pavlovic s. Prostate. 2020 Nov;80(15):1297-1303. doi: 10.1002/pros.24051. Epub 2020 Aug 24. Prostate. 2020. PMID: 32833288 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

93 results

Search Page